Massive Transfusion Protocols, Trauma-Induced Coagulopathy, and Damage-Control Resuscitation

Massive transfusion is the rapid replacement of a large fraction of a patient's blood volume during catastrophic haemorrhage, most often after major trauma. Modern practice pairs predefined massive transfusion protocols with damage-control resuscitation, giving plasma, platelets, and red cells in balanced proportions to treat the coagulopathy that accompanies severe bleeding rather than to chase it after it develops.

Definition

Massive transfusion and coagulopathy management is the integrated approach to exsanguinating haemorrhage that combines protocolised delivery of blood components in balanced ratios, correction of trauma-induced coagulopathy, and damage-control resuscitation aimed at restoring haemostasis and perfusion.

Scope

This topic covers the physiology of trauma-induced coagulopathy, the rationale for balanced (approximately 1:1:1) component ratios, the structure of massive transfusion protocols, the principles of damage-control resuscitation, and the adjunctive use of antifibrinolytic therapy. It is a reference account of how exsanguinating haemorrhage is approached and is not a resuscitation protocol for individual care.

Core questions

• What is trauma-induced coagulopathy and why does it develop early in severe bleeding?
• Why are blood components given in balanced ratios during massive haemorrhage?
• What is a massive transfusion protocol and what does damage-control resuscitation entail?
• What is the role of antifibrinolytic therapy in major traumatic bleeding?

Key concepts

• Trauma-induced coagulopathy
• Balanced (1:1:1) component ratio
• Massive transfusion protocol
• Damage-control resuscitation
• Permissive hypotension
• Antifibrinolytic therapy

Mechanisms

Severe injury and shock provoke an early endogenous coagulopathy, which is then worsened by haemodilution, acidosis, and hypothermia — the so-called lethal triad. Damage-control resuscitation counters this by limiting crystalloid, transfusing balanced proportions of plasma, platelets, and red cells to reconstitute something close to whole blood, and rapidly controlling the source of bleeding. The PROPPR trial compared a 1:1:1 with a 1:1:2 ratio and, although mortality at 24 hours and 30 days did not differ significantly, more patients in the balanced-ratio arm achieved haemostasis and fewer died of exsanguination, supporting balanced resuscitation (holcomb-2015). Antifibrinolytic therapy with tranexamic acid reduced mortality in bleeding trauma patients in the CRASH-2 trial, particularly when given early (crash2-2010). Combat-casualty data showing that most potentially survivable deaths are from haemorrhage motivated this resuscitation paradigm (eastridge-2012).

Clinical relevance

An understanding of trauma-induced coagulopathy and balanced resuscitation underlies how trauma systems organise blood delivery and why massive transfusion protocols exist. This entry explains the concepts and evidence; it does not provide ratios, doses, or timing for treating an individual patient, which depend on clinical judgement and local protocols.

Epidemiology

Haemorrhage is the leading cause of potentially preventable death after injury, and analyses of combat casualties found that the majority of survivable deaths were due to bleeding, much of it from non-compressible sources — a finding that shaped civilian and military resuscitation practice (eastridge-2012).

Evidence & guidelines

Balanced component resuscitation is supported by the PROPPR trial and codified in trauma practice guidelines such as those of the Eastern Association for the Surgery of Trauma, while early tranexamic acid is supported by CRASH-2 (holcomb-2015, cannon-2017, crash2-2010).

History

Damage-control resuscitation emerged from military experience in the early twenty-first century, where high-ratio component transfusion and early haemorrhage control appeared to improve survival. These observations were translated into civilian massive transfusion protocols and tested in randomised trials, while CRASH-2 established a role for antifibrinolytics in bleeding trauma (eastridge-2012, holcomb-2015, crash2-2010).

Debates

Is a strict 1:1:1 ratio the right target?

The PROPPR trial did not show a significant mortality difference between 1:1:1 and 1:1:2 ratios overall, but favourable secondary outcomes support balanced resuscitation; the precise optimal ratio and the role of whole blood remain debated.

Key figures

• John Holcomb

Seminal works

• holcomb-2015
• crash2-2010
• eastridge-2012

Frequently asked questions

What is damage-control resuscitation?

It is an approach to severe haemorrhage that minimises crystalloid fluids, transfuses plasma, platelets, and red cells in balanced proportions, and prioritises rapid control of the bleeding source to limit coagulopathy and the lethal triad of acidosis, hypothermia, and coagulopathy.

Why give plasma and platelets along with red cells in massive bleeding?

Replacing only red cells dilutes clotting factors and platelets and worsens coagulopathy; balanced transfusion of all three components aims to reconstitute something closer to whole blood and support haemostasis.